NASDAQ : PTGX
Protagonist Therapeutics, Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 144.85 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 9.37B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 9.37B |
| Enterprise Value | 8.53B |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 13, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 64.71M |
| Shares Outstanding | 64.71M |
| Shares Change (YoY) | +4.05% |
| Shares Change (QoQ) | +0.73% |
| Owned by Insiders (%) | 0.60% |
| Owned by Institutions (%) | 101.96% |
| Float | 52.89M |
Ratios
| Measure | Value |
|---|
| PE Ratio | 118.61 |
| Forward PE | 67.82 |
| PS Ratio | 33.24 |
| Forward PS | 23.99 |
| PB Ratio | 11.13 |
| P/TBV Ratio | 11.14 |
| P/FCF Ratio | 71.78 |
| P/OCF Ratio | 71.44 |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | 102.92 |
| EV / Sales | 30.26 |
| EV / EBITDA | 142.49 |
| EV / EBIT | 146.25 |
| EV / FCF | 65.34 |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 21.71 |
| Quick Ratio | 21.58 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | 0.15 |
| Debt / FCF | 0.07 |
| Interest Coverage | n/a |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | 10.98% |
| Return on Assets (ROA) | 4.55% |
| Return on Invested Capital (ROIC) | 61.79% |
| Return on Capital Employed (ROCE) | 6.88% |
| Weighted Average Cost of Capital (WACC) | 12.62% |
| Revenue Per Employee | $2.00M |
| Profits Per Employee | $588,007 |
| Employee Count | 141 |
| Asset Turnover | 0.35 |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | 1.43M |
| Effective Tax Rate | 1.69% |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 1.52 |
| 52-Week Price Change | +88.88% |
| 50-Day Moving Average | 142.93 |
| 200-Day Moving Average | 116.62 |
| Relative Strength Index (RSI) | 57.91 |
| Average Volume (20 Days) | 734,615 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 10.30M |
| Short Previous Month | 9.35M |
| Short % of Shares Out | 15.91% |
| Short % of Float | 19.47% |
| Short Ratio (days to cover) | 12.29 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 281.99M |
| Gross Profit | 281.99M |
| Operating Income | 58.34M |
| Pretax Income | 84.34M |
| Net Income | 82.91M |
| EBITDA | 59.88M |
| EBIT | 58.34M |
| Earnings Per Share (EPS) | $1.22 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 782.58M |
| Total Debt | 9.22M |
| Net Cash | 840.24M |
| Net Cash Per Share | $12.98 |
| Equity (Book Value) | 841.54M |
| Book Value Per Share | 13.01 |
| Working Capital | 769.97M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | 131.20M |
| Capital Expenditures | -615,000 |
| Depreciation & Amortization | 1.54M |
| Net Borrowing | n/a |
| Free Cash Flow | 130.58M |
| FCF Per Share | $2.02 |
Margins
| Measure | Value |
|---|
| Gross Margin | 100.00% |
| Operating Margin | 20.69% |
| Pretax Margin | 29.91% |
| Profit Margin | 29.40% |
| EBITDA Margin | 21.24% |
| EBIT Margin | 20.69% |
| FCF Margin | 46.31% |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -4.05% |
| Shareholder Yield | -4.05% |
| Earnings Yield | 0.84% |
| FCF Yield | 1.39% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $178.57 |
| Price Target Difference | 23.28% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 14 |
| Revenue Growth Forecast (3Y) | 100.69% |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | 72.22 |
| Piotroski F-Score | 6 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | |
| Graham Upside | |